STADA Portugal continues to strengthen its role as a reliable partner to patients, healthcare professionals and customers, namely with special initiatives during the coronavirus crisis. In line with the company’s purpose of caring for people’s health as a trusted partner, its dedicated employees work with great agility and persistence to keep supplying medicines while enabling Pharmacies to implement innovative offerings that address the increased and differentiated needs of their patients.

In our current innovation pipeline, we highlight two pioneering solutions co-created with local health care experts. These projects are tailormade for Portuguese Pharmacies aiming to upgrade their services, namely evolving their digital capabilities and enriching the interactions that take place with patients, as well as, upskilling competences of pharmacy professionals for COVID19 prevention and diagnosis.

Furthermore, STADA’s portfolio has been expanding significantly and will soon be strengthened with an innovative therapy used for treating late-stage Parkinson’s disease, a patented gel formulation of levodopa, carbidopa and entacapone. With the integration of this product, STADA will be immediately supplying Sweden, Denmark, Norway and Finland while seeking regulatory approval via Europe’s mutual recognition process in several key European countries. Accordingly, we can anticipate this innovative treatment to be made available to Portuguese patients in the near future.

“These are just illustrative testimonies of STADA’s strong focus on innovation at global scale, with the commitment and entrepreneurship of all our employees as the base of our success. stada.pt.

This resolute is fully materialized by STADA Portugal, reinforcing its position as leading go-topartner for specialty pharmaceuticals, generics and consumer health products, investing and nurturing innovation in health care for the Portuguese patients”, says Tiago Baleizão, General Manager of STADA Portugal.